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factor VIII (FVIII) deﬁciency. We previously demonstrated
that FVIII is produced speciﬁcally in liver sinusoid endothelial
cells (LSECs) and to some degree in myeloid cells, and thus, in
the present work, we seek to restrict the expression of FVIII
transgene to these cells using cell-speciﬁc promoters. With
this approach, we aim to limit immune response in a mouse
model by lentiviral vector (LV)-mediated gene therapy encod-
ing FVIII. To increase the target speciﬁcity of FVIII expression,
we included miRNA target sequences (miRTs) (i.e., miRT-
142.3p, miRT-126, and miRT-122) to silence expression in
hematopoietic cells, endothelial cells, and hepatocytes, respec-
tively. Notably, we report, for the ﬁrst time, therapeutic levels
of FVIII transgene expression at its natural site of production,
which occurred without the formation of neutralizing anti-
bodies (inhibitors). Moreover, inhibitors were eradicated in
FVIII pre-immune mice through a regulatory T cell-dependent
mechanism. In conclusion, targeting FVIII expression to
LSECs and myeloid cells by using LVs with cell-speciﬁc pro-
moter minimized off-target expression and immune responses.
Therefore, at least for some transgenes, expression at the phys-
iologic site of synthesis can enhance efﬁcacy and safety, result-
ing in long-term correction of genetic diseases such as HA.Received 20 January 2017; accepted 28 April 2017;
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Hemophilia A (HA) is an X-linked bleeding disorder affecting 1 in
5,000–10,000 live male births and is caused by mutations and/or dele-
tion in the coagulation factor VIII (FVIII) gene.1–3 Currently, there is
no deﬁnitive cure for HA, and patients are treated with infusions of
FVIII concentrate to treat or prevent bleeding, the latter aimed at sus-
taining FVIII levels at or above 1% of normal as prophylaxis. There-
fore, because HA is amonogenic disease, and evenmodest amounts of
FVIII (R1%) can ameliorate the bleeding phenotype and improve the
quality of life of affected individuals, the potential of gene therapy rep-
resents a powerful solution for the permanent treatment of HA.4
Recently, hemophilia B (HB) adult patients were successfully treated
with the administration of a single dose of adeno-associated virus
(AAV)-derived vectors expressing human factor IX (FIX) in hepato-cytes, resulting in long-term FIX activity.5 Moreover, hepatocyte-spe-
ciﬁc FIX expression using AAV reached therapeutic levels in HB dogs
even in the presence of neutralizing antibodies to canine FIX.6
Similarly, hepatocyte-speciﬁc FIX expression by lentiviral vectors
(LVs)7–10 with the presence of the hematopoietic-speciﬁc microRNA
target sequence (mirT) for miR-142-3p11 prevented off-target expres-
sion in antigen-presenting cells (APCs) with long-term expression
and avoidance of immune response. This approach was successfully
applied in dogs and is now under clinical development in humans.12
Thus, circumventing the immune response to FVIII may also enable a
gene therapy approach for HA, warranting effort in additional to
that focused on improving hepatocyte-targeted LV-induced FVIII
expression.13–15
From the gene therapy perspective, there are twomajor differences be-
tweenHA andHB: (1) the normal site of synthesis of mouse or human
FVIII is not the hepatocytes, and (2) risk for the formation of long-last-
ing inhibitor formation to FVIII in HA is 5-fold higher (20%–30% of
patients) compared with those receiving replacement therapy for HB.
Notably, in AAV-induced hepatocyte expression of human FVIII,
FVIII inhibitor develops frequently, whereas using a similar approach,
no FIX inhibitor is observed in HB mice injected with AAV-human
FIX.16 Similarly, AAV liver gene therapy induced human FVIII
expression in non-human primates (NHPs) resulted in inhibition in
almost all animals and again in only 20% of those NHPs injected
with AAV-human FIX. Whether these discrepancies are due to the
use of non-species-speciﬁc and/or ectopic expression is unknown.
Recent studies have demonstrated that FVIII is not secreted by hepa-
tocytes but mainly, although not exclusively, by endothelial cellsMolecular Therapy Vol. 25 No 8 August 2017 ª 2017 1815
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www.moleculartherapy.org(ECs).17–19 These cells simultaneously synthesize and release von
Willebrand factor (vWF), which stabilizes and protects FVIII against
premature degradation.20,21 The liver is known to induce tolerance,
rather than immunity, toward antigens presented locally to
T cells22,23 by specialized resident cells, such as liver sinusoidal ECs
(LSECs) and resident liver macrophages, or Kupffer cells (KCs),
which express anti-inﬂammatory mediators (e.g., interleukin 10
[IL-10], transforming growth factor b [TGF-b]),24,25 thereby direct-
ing the immune response toward tolerance.26 Moreover, LSECs and
KCs were reported to produce and secrete FVIII when transplanted
in a murine model of HA.17,27 Our goal is to test whether expression
of human FVIII in its physiologic site of synthesis is feasible without
increased immunogenicity.
To achieve transgene expression only in certain cell types, cell-speciﬁc
promoters are widely used, such as the endothelial-speciﬁc promoter
cadherin 5 type 2, also known as vascular endothelial cadherin
(VEC),28 the myeloid speciﬁc CD11b promoter, or ItgaM.29 VEC is
a transmembrane protein expressed mainly in ECs with a particular
role in EC biology controlling intercellular cell junctions.28 CD11b
is a leukocyte adhesion molecule, expressed mainly in monocytes
and macrophages, which mediates myeloid cells binding to ECs and
their migration through the vascular wall.30 In addition, speciﬁc
miRTs can be included in the 30 UTR of the transgene sequence to
improve the stringency of transgene expression regulation.8,31 In
our studies, we use three different miRTs, miRT-122, miRT-126,
and miRT-142-3p. miR-122 is a hepatocyte-speciﬁc microRNA
with an important role in liver development and liver diseases.32
miR-142-3p is a miRNA expressed mainly in hematopoietic cells.11
miR-126 is a microRNA expressed predominantly by ECs controlling
angiogenesis33,34 and plasmacytoid dendritic cells (pDCs), as recently
reported.35
Thus, miRTs provide post-transcriptional control to restrict trans-
gene expression in targeted cells. Several efforts were focused on the
improvement of LV for FVIII to obtain targeted transgene expres-
sion36 and on the production of several bioengineered FVIII com-
pounds.36,37 However, the development of gene therapy for HA is
hampered by the increased risk for developing inhibitory antibodies
to FVIII.38 In previous reports, the addition of miRT-142-3p to
FVIII-expressing LV under the control of a hepatocyte-speciﬁc pro-
moter was unable to prevent the production of neutralizing anti-
bodies in HA mice.13,31,39 Consequently, a persistent unmet need
exists to develop new strategies to minimize immune response asso-
ciated with FVIII expression after gene therapy.Figure 1. Endothelial- and Myeloid-Specific Transgene Expression in the Liver
(A–E) GFP expression in the liver and the spleen of mice injected with LV.VEC-GFP-miRT
or LV.CD11b-GFP ±miRT-126 (n = 9) (D and E) 1 week and 3months after injection. Afte
endothelial cells, with some off-targets in hepatocytes (white arrowheads) and myel
expression in hematopoietic cells but not in hepatocytes (C). The addition of the miRT-1
cell types, as shown by the co-staining of the endothelial marker Lyve-1(red) with the GF
mainly in hepatic and splenic myeloid cells, with few GFP-expressing endothelial cells (
detected only in myeloid cells, as shown by co-staining for the macrophage marker F4In this study, we describe new LV expression cassettes containing
GFP and/or the B domain-deleted human FVIII (BDD-hFVIII) under
the control of two cell-speciﬁc promoters, VEC28,40 and CD11b.29
Post-transcriptional regulation was combined with different combi-
nations of miRTs to simultaneously obtain long-term transgene
expression and functional secretion of therapeutic doses of FVIII
and to prevent immune response. Our model is innovative and has
two advantages over AAV: (1) neutralizing antibodies do not develop,
supporting this approach as viable therapy for a large fraction of HA
patients, and (2) upregulation of memory T cells does not occur, pre-
venting vector-capsid immune responses observed in early infection
with AAV. This strategy is poised to improve FVIII gene transfer
for HA and has additional potential application for inducing toler-
ance as well as safe and effective expression during gene therapy for
other disease conditions. In particular, the present study may open
new perspectives for the treatment of HA patients who have or are
prone to develop anti-FVIII antibodies.
RESULTS
In Vivo GFP Expression by LV Carrying the VEC Promoter and
miRT122–142
Delivery of LV by intravascular injection transduces mainly the
liver and spleen. To restrict transgene expression in the endothelial
cells (ECs) of these organs, we built an LV construct containing
the endothelial-speciﬁc murine VEC promoter with miRT122 and
miRT142-3p to prevent expression in hepatocytes and hematopoietic
cells, respectively (Figure S1A). We administered 5  108 TU of
LV.VEC-GFP miRT122-miRT142-3p into C57BL/6 mice (n = 9)
by the tail vein and analyzed the liver and spleen of injected mice af-
ter 1, 4, and 12 weeks. GFP expression in liver was stable for up to
3 months, the longest time tested, largely in the endothelium and
mostly in LSECs, without signiﬁcant immune or inﬂammatory cell
inﬁltrate accumulation in the parenchyma (not shown). In the spleen
of injected mice, GFP expression was restricted to the endothelium
inside and surrounding the white pulp. In addition, miRT-122 and
miRT-142-3p inclusion efﬁciently prevents “off-target” transgene
expression in hepatocytes and hematopoietic cells, respectively, as-
suring long-term transgene expression in ECs (Figure 1A). As con-
trol, we injected mice with an LV containing only the VEC promoter
and GFP (Figure S1A), and we observed off-target GFP expression in
a very small fraction of hepatocytes and hematopoietic cells (Fig-
ure 1B). The expression cassette (LV.VEC-GFP-142) (Figure S1A)
restricted GFP expression to ECs, preventing expression in hemato-
poietic cells, though a few GFP+ hepatocytes were still present
(Figure 1C), conﬁrming that the presence of both miRT and theof LV-Injected Mice
-122–142 (n = 9) (A), LV.VEC-GFP (n = 9) (B), LV.VEC-GFP-miRT-142-3p (n = 9) (C),
r injection of LV.VEC-GFP, transgene expression was observed in LSECs and splenic
oid cells (white arrows) (B). The addition of the miRT-142-3p avoided transgene
22–142-3p restricted GFP expression to endothelial cells without off-targets in other
P (green) (A). After injection of LV.CD11b-GFP, transgene expression was observed
white arrows) (E); by adding miRT-126 to the construct transgene, expression was
/80 (red) and GFP (green) (D). The scale bars represent 25 mm.
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(Figure 1A).
In Vivo Expression of LV Carrying the CD11b Promoter and
miRT-126
Similarly, to restrict transgene expression to myeloid cells, such as he-
patic macrophages, or Kupffer cells (KCs), splenic monocytes, and
macrophages, we prepared an LV containing four copies of the
miRT-126 containing GFP under the control of the myeloid-speciﬁc
CD11b promoter (LV.CD11b-GFP-126) (Figure S1A). In C57BL/6
mice, this vector restricted transgene expression in myeloid cells.
GFP expression was maintained up to 3 months after LV injection,
the longest time tested, preventing off-target transgene expression
in ECs both in liver and spleen (Figure 1D), with no inﬂammatory in-
ﬁltrates accumulating in the liver parenchyma (not shown) of injected
mice. As control, we injected C57BL/6 mice (n = 9) with 5  108 TU
of LV containing only the CD11b promoter and GFP as a transgene
(LV.CD11b-GFP)29 (Figure S1A). As expected, GFP expression was
detected mainly in the monocyte/macrophage compartment of liver
and splenic red pulp, with the presence of some off-target expression
in ECs, but no GFP+ hepatocytes were detected (Figure 1E).
Endothelial and Myeloid Cell-Specific Transgene Expression
Facilitates Stable hBDD-FVIII Secretion and Reduces Clotting
Times in HA Mice
To evaluate hFVIII expression in ECs, we prepared LV expressing
BDD-hFVIII under the control of the VEC promoter (LV.VEC-
hFVIII) ± miRT-122 and miRT-142-3p sequences (LV.VEC-
hFVIII-122–142) (Figure S1B). Eight- to 10-week-old C57BL/6 HA
mice were tail-vein-injected with 109 TU of these constructs
(n = 5–9); all injected mice had sustained hFVIII expression for up
to 1 year after vector delivery (Figures 2A and 2E). Both groups of
mice (i.e., LV.VEC-FVIII and LV.VEC-FVIII-122–142 treated)
demonstrate 5%–6% of hFVIII activity. Moreover, ELISA detected
no anti-FVIII antibodies, indicating that treatment with LV.VEC-
hFVIII ± miRT-122–142-3p did not trigger a humoral immune
response in these mice (Figures 2C and 2G).
On the contrary, intravenous injection of LV containing hFVIII ex-
pressed under the control of the ubiquitous PGK promoter with or
without the miRT-142-3p sequences (109 TU of LV.PGK-hFVIII ±
142 [n = 5]) in HA mice (Figure S2A) yielded no more than 1.5%
FVIII activity 2 weeks after injection, decreasing below 0.5% there-
after (Figure S2B). All mice injected with both LV ± miRT-142-3p
sequences developed inhibitors, as assessed by Bethesda assay (Fig-
ure S2C), and anti-FVIII IgG1, IgG2a, and IgG2b were detected by
ELISA (Figures S2D–S2F). Interestingly, the addition of miRT-
142-3p was sufﬁcient to reduce inhibitor titers (30%–40%) (Fig-
ure S2C), showing that in HA mice, miRT-142-3p reduces but does
not eliminate the immune response against hFVIII expressed under
the control of a ubiquitous promoter.
To address the expression of hFVIII in myeloid cells, we tail-vein-
injected 109 TU of an LV expressing the BDD-hFVIII transgene1818 Molecular Therapy Vol. 25 No 8 August 2017under the control of the CD11b promoter (LV.CD11b-hFVIII) ±
miRT-126 (LV.CD11b-hFVIII-126) (Figure S1B) in 8- to 10-week-
old C57BL/6 HA mice (n = 5–10). As observed for the LV.VEC-
injected mice, both mouse groups showed long-term sustained
hFVIII expression for up to 1 year, with an average of 5%–6% activity
(Figures 2B and 2F). Interestingly, 30% of the mice injected with
LV.CD11b-hFVIII (n = 10) developed anti-FVIII antibodies
8–12 weeks after LV injection (Figure 2D), and these mice died
mainly from internal or intracranial bleeding 1–2 weeks after devel-
oping anti-FVIII antibodies, while none of the mice injected with
LV.CD11b-hFVIII-126 (n = 5) developed antibodies (Figure 2H)
and continued to express FVIII.
Mice injected with LV.VEC-hFVIII-122–142 and with LV.CD11b-
hFVIII-126 were then immunized with 20 mg of a commercial recom-
binant human BDD-hFVIII (ReFacto, Pﬁzer) in incomplete Freund’s
adjuvant (IFA). This immunization challenge did not result in the
development of anti-FVIII antibodies (Figures 2D and 2H), conﬁrm-
ing that immune tolerance was achieved consistent with the contin-
uous secretion of FVIII in the circulation.
Integrated vector copy number was measured by qPCR in the liver
and spleen of injected mice. In KCs and LSECs (Figures S3A and
S3B) isolated from liver of both LV.VEC-hFVIII ± miRT-122–142-
3p-injected mice and LV.CD11b.hFVIII ± miRT-126-injected mice
(Figures S3C and S3D) an average of one or two copies per genome
were found. hFVIII expression in LSECs and in macrophages
of LV-injected mice was conﬁrmed by immunohistochemistry of
liver and spleen sections (Figures 3A–3F).These data indicate that
all the LVs were stably integrated and that the transduced cells
were not cleared but persisted for a long period of time in the
treated mice.
Endothelial-Specific Expression Allows hFVIII Secretion and
Results in the Reversion of Anti-FVIII Antibody Titer in Previously
Immunized Mice
One of the major obstacles for HA gene therapy is the treatment of
inhibitor-positive patients.41 Hepatocyte-speciﬁc FIX expression
results in the reduction of anti-FIX antibody titers in previously
FIX-immunized HB mice.7 However, reduction of anti-FVIII anti-
body titers using gene therapy in previously FVIII-immunized HA
mice requires the additional treatment with anti-CD3 or anti-CD20
antibodies.42,43 We therefore induced anti-FVIII antibodies in
C57BL/6 HA mice by subcutaneous injection of human recombinant
FVIII (ReFacto) in IFA7 (Figure S4). All mice developed 15–24
Bethesda unit (BU) inhibitor titers 4 weeks following immunization
(Figure 4C). These immunized mice were injected with 109 TU of
LV.VEC-hFVIII ± miRT-122–142-3p (n = 3). One week following
LV injection, mice expressed an average of 1% hFVIII with a stable
increase to 5%–6% in hFVIII activity for 1 year following injection
(Figures 4A and 4B). Concurrently, plasma BU decreased progres-
sively starting from 4 weeks after LV injection (Figure 4C). We antic-
ipate that because plasma anti-FVIII IgG1 decreased in parallel with
BU in injected mice, anti-FVIII inhibitors are IgG1 isotype antibodies
Figure 2. Long-Term hFVIII Expression in HA Mice after Injection of LV.VEC-hFVIII ± miRT-122–142-3p and LV.CD11b-hFVIII ± miRT-126
(A–H) HA mice were injected for the expression of hFVIII in endothelial cells with the LV containing the endothelial-specific VEC promoter with (n = 9) or without (n = 5) the
addition of miRT-122–142-3p (A, C, E, and G) or in myeloid cells with the LV containing the myeloid-specific CD11b promoter with (n = 5) or without (n = 5) the addition of
miRT-126 (B, D, F, and H). (A, B, E, and F) Graphs showing themean percentages ±SD of hFVIII activity in plasma of HAmice up to 1 year after LV injection. Mice injectedwith
VEC-hFVIII-122–142 (E) or CD11b-hFVIII-126 (F) were immunized with a subcutaneous injection of hFVIII in incomplete Freund’s adjuvant (IFA) (A, B, E, and F: p < 0.001
compared with control HA group). (C, D, G, and H) ELISA showing the presence of anti-FVIII antibodies in plasma of LV injected mice (means ± SD). No anti-FVIII antibodies
were detected in plasma of HAmice injected with LV.VEC-hFVIII ±miRT-122–142-3p (C and G) or CD11b-hFVIII-126 (H). Thirty percent of HAmice injected with LV.CD11b-
hFVIII developed anti-FVIII antibodies between 8 and 12weeks after LV injection (D). Plasma dilution was 1:2,000. Ctr+, pooled plasma from LV.PGK-hFVIII-injected mice that
developed anti-FVIII antibodies.
www.moleculartherapy.org
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Figure 3. hFVIII Expression in Hepatic and Splenic
Endothelial Cells and Myeloid Cells of HA Mice
1 Year after LV Injection
(A–F) Immunohistochemistry showing hFVIII expression in
hepatic and splenic endothelial cells after injection of
LV.VEC-hFVIII-122–142 (A and B) and in hepatic and
splenic myeloid cells after injection of LV.CD11b-hFVIII-
126 (C and D). Control liver and spleen from HA mice
showed no hFVIII positive staining (E and F). The scale
bars represent 100 mm.
Molecular Therapy(Figure 4D), in contrast to anti-FVIII IgG2a and IgG2b antibodies,
which remained detectable in injected mice (Figures 4E and 4F).
To evaluate the potential of this LV delivery approach to induce
immune tolerance to FVIII, we injected these LV-treated mice with
4 U of human recombinant FVIII (ReFacto)44 24 weeks after LV de-
livery and demonstrate that antibody titers remained undetectable
with continued FVIII activity, indicating tolerance to FVIII (Figures
4A–4E).
Our present data demonstrate that we were even able to reverse the
pre-existing anti-FVIII immunity in HA mice. Indeed, inhibitors
levels in the plasma of these mice decreased, with a concomitant
correlated increase of FVIII activity. Similar results were reported
in the case of the hepatocyte-directed FIX expression mediated by
LVs containing mirT-142-3p, which was able to reverse anti-FIX
pre-existing immunity in HB mice.71820 Molecular Therapy Vol. 25 No 8 August 2017miRT-126 Prevents Transgene Expression
in pDCs
As previously described, pDCs express miR-
126.35 We therefore hypothesized that the addi-
tion of miRT-126 would also reduce transgene
expression in pDCs, blunting the immune
response to FVIII. Initially, C57BL/6 mice
were injected with 5  108 TU of LV.CD11b-
GFP ± miRT-126 (n = 6–7) or LV.PGK-GFP
(n = 6), and GFP expression was analyzed in he-
patic and splenic pDCs 2 weeks following injec-
tion. Fluorescence-activated cell sorting (FACS)
analysis demonstrates GFP expression in pDCs
of mice injected with either LV.PGK-GFP or
LV.CD11b-GFP. Transgene expression, instead,
was drastically reduced only in pDCs but not in
other cell types after injection of LV.CD11b-
GFP-126 (% of GFP+ pDCs: CD11b-GFP
12 ± 3 versus CD11b-GFP-126 1.8 ± 0.5 in liver
and CD11b-GFP 15 ± 3 versus CD11b-GFP-
126 1.3 ± 0.6 in spleen; p < 0.01), with no effects
on the total number of splenic and hepatic
pDCs. Moreover, we observed comparable
GFP expression in DCs in mice treated with
and without miRT-126 (Figures 5A and 5B).We hypothesize that these data may explain the development of
anti-FVIII antibodies in 30% of LV.CD11b-hFVIII-injected mice.
Perhaps presentation of FVIII antigen by pDCs is able to trigger an
immune response in injected mice; the addition of miRT-126 abro-
gated this response, allowing long-term FVIII expression in LV-
treated HA mice.
Endothelial-Specific Expression of FVIII-RH and
Codon-Optimized FVIII Results in Higher FVIII Activity without
Antibody Formation
We recently described a codon-optimized (co)-hFVIII version that
augments gene expression in vivo.45 To study the efﬁciency of an endo-
thelial-speciﬁc expression system and evaluate the possibility of
improving transgene expression, we compared the non-codon-opti-
mized BDD-hFVIII version (LV.VEC-hFVIII ± 122–142) with its
co-hFVIII counterpart (LV.VEC-co-hFVIII-122–142) (n = 3–5 for
Figure 4. hFVIII Activity after LV.VEC-hFVIII ± miRT-122–142-3p Injection in HA Mice Previously Immunized with hFVIII
HA mice were immunized with FVIII, and 4 weeks later injected with LV.VEC-hFVIII ± 122–142. (A and B) hFVIII activity in plasma of mice injected with LV.VEC-hFVIII (A) and
LV.VEC-hFVIII-122–142 (B) increased over time, reaching 5%–6% FVIII activity, and remained stable up to 1 year. Rechallenge with hFVIII had no effects on hFVIII activity in
plasma of both groups of mice (A and B: p < 0.001 compared with control group). (C) BU present in plasma of immunizedmice decreased over time after injection of LV.VEC-
hFVIII ± 122–142. (D–F) Line-graphs showing anti-FVIII IgG1 (D), IgG2a (E), and IgG2b (F) antibody titers in plasma of FVIII-immunized HA mice injected with LV.VEC-hFVIII
and LV.VEC-hFVIII-122–142 (C–F: p < 0.001 compared with control group). Indicated are means ± SD.
www.moleculartherapy.orgeach LV). We also compared these forms with the RH-FVIII form,
a recently described FVIII variant with enhanced pro-coagulant activ-
ity inHAmice. This variant (RH-FVIII) contain an amino acid change
at the furin cleavage site within the B domain (position R1645H) that
mimics the canine sequence (HHQR versus human RHQR).46 Two
weeks after LV.VEC-co-hFVIII-122–142 injection, HA mice showed
higher FVIII activity; the FVIII activity inmice injectedwith co-hFVIII
increased over time up to 12%, remaining stable up to 36 weeks
following injection. In comparison, LV injection with LV.VEC-
hFVIII ± 122–142 exhibited the typical FVIII activity (up to 5%), re-maining stable 52 weeks following vector delivery (Figure 6A), while
LV.VEC-RH reached 8% FVIII activity (higher than LV.VEC-
hFVIII ± 122–142 but lower than co-hFVIII) and remained stable
for 1 year following LV injection. As observed for the BDD-hFVIII
form, no anti-FVIII antibodies or inhibitors were detectable in the
plasma of mice injected with LV.VEC-co-hFVIII-122–142 or
LV.VEC-RH (Figure 6B). Moreover, FVIII immunization did not
result in anti-FVIII antibody production, and FVIII activity remained
stable inLV-injectedmice (Figures 6Aand6B). Blood loss andbleeding
time analyzed 24 weeks after LV injection conﬁrmed correction in allMolecular Therapy Vol. 25 No 8 August 2017 1821
Figure 5. GFP Expression in Hepatic and Splenic
Plasmacytoid Dendritic Cells after Injection of
LV.CD11b-GFP ± miRT-126
(A and B) FACS analysis showing GFP expression in
pDCs (CD11c+, B220+, pDCA-1+) and in DCs (CD11c+,
pDCA-1) from liver (A) and spleen (B) of mice injected
with LV.CD11b-GFP ± miRT-126. Mice injected with the
LV.PGK-GFP were used as controls. The addition of
miRT-126 to the LV.CD11b-GFP drastically reduced the
GFP expression in hepatic and splenic pDCs. Indicated
are mean percentages ± SD (n = 6 or 7 per group).
Molecular Therapyinjectedmice, with higher efﬁciency inmice injected with LV.VEC-co-
hFVIII-122–142 (Figures 6C and 6D). Taken together, these data
demonstrate that endothelial-speciﬁc FVIII expression is improved
by using a codon-usage-optimized hFVIII or a different FVIII form
with greater pro-coagulant activity.
LSEC-Induced Regulatory T Cells Allow Tolerance to FVIII
To study whether long term FVIII expression in LSECs was regulated
by regulatory T cells (Tregs), we depleted Tregs in vivo using an anti-
CD25 antibody.47 We have explored the ability of LSECs to induce
Tregs using twodifferent protocols: (1) LV-VEC-hFVIII± 122–142 in-
jection in HAmice followed by Treg depletion (Figures S5A and S5B)
and (2) an initial Treg depletion followed by injection of LV-VEC-
hFVIII ± 122–142 (Figures S5C and S5D).48 For the ﬁrst group of
mice, we injected LV.VEC-hFVIII± 122–142 (n = 5), assessing plasma
hFVIII activity and anti-hFVIII antibodies starting 1 week after LV de-
livery. After 10 weeks, hFVIII activity was stable (Figure 7A), and no
anti-hFVIII antibodies were detected (Figures 7B–7E). Eleven weeks
after LV injection, we depleted Tregs using anti-CD25 and analyzed
plasma samples from the subsequent week. After 1 week, Tregs were
almost totally depleted (Figure S5B), with no effect on hFVIII activity
or anti-hFVIII antibody production. Three weeks after Treg depletion,
hFVIII activity in the plasma of all mice was halved (Figure 7A), and
5 weeks after Treg depletion, anti-hFVIII antibodies and inhibitors
were detectable (Figures 7B–7E) even though Tregs were almost
back to normal (Figure S5B). Anti-FVIII antibodies and plasma BU
peaked at 12 weeks following Treg depletion in injected mice (Figures
7B–7E)with undetectable plasmahFVIII activity (Figure 7A). Interest-
ingly, 16 weeks after Treg depletion, plasma hFVIII activity rebounds,
returning to the original levels observed before Treg depletion (Fig-
ure 7A) 3 weeks later, with a concurrent decrease in BU levels (Fig-
ure 7B).Moreover, blood loss and bleeding time after tail clip challenge
conﬁrms the physiological function of restored FVIII activity to the
initial levels before Treg depletion (Figures 7F and 7G). Again, BU ki-1822 Molecular Therapy Vol. 25 No 8 August 2017netics correlate mainly with anti-FVIII IgG1
while anti-FVIII IgG2a and IgG2b remained sta-
ble after the immunization (Figures 7B–7E).
In the second group of animals, we depleted
Tregs by injection of anti-CD25 antibodies
(n = 6) with complete Treg depletion in5 days; mice were then injected with LV-VEC-hFVIII ± 122–142
(n = 3 for each group) (Figures S5C and S5D). We analyzed plasma
samples of injected mice for the presence of hFVIII activity, BU,
and anti-hFVIII antibodies starting 2 weeks after LV injection. All
of these mice showed only very low hFVIII activity in plasma (<1%)
up to 52 weeks after LV injection (Figure S6A) and developed anti-
hFVIII antibodies and inhibitors starting 2 weeks after LV-injection
(Figures S6B–S6E). These data demonstrate a clear role for Tregs in
establishing tolerance to FVIII during LV-induced gene expression
in ECs under the VEC promoter. Similar results were reported for
mice immunized with FIX and injected with an AAV containing
the FIX transgene under a hepatocyte-speciﬁc promoter.49 Overall,
LSECs appear to be the ideal target cell for FVIII transgene expression.
Endothelial-Specific Expression of FVIII in BALB/c and B6/129
HA mice
To this point, we analyzed HA mice on a C57BL/6 background. To
study whether endothelial-speciﬁc FVIII production would support
long-term transgene expression in a different immunocompetent
mouse strain,50 we injected BALB/c (n = 4) and B6/129 (n = 5) HA
mice with LV.VEC-hFVIII. Two weeks after LV injection, plasma
FVIII activity is detected in treated BALB/c and B6/129 mice up to
28 and 24 weeks after injection, respectively, with comparable activity
(5%–6%) with that observed with immunocompetent C57BL/6 HA
mouse (Figures 8A and 8C). Moreover, no plasma anti-FVIII anti-
bodies were detected in either LV injected HA mouse strain (Figures
8B and 8D) with diminished blood loss and shortened bleeding time
at 28 and 20 weeks after injection in BALB/c and B6/129 HA mice,
respectively, conﬁrming that correction was achieved in all injected
mice (Figures 8E and 8F).
Finally, we performed a direct comparison to verify if there is any
discrepancy between the FVIII activity measured by activated partial
thromboplastin time (aPTT) or by chromogenic assays. We tested in
Figure 6. Comparison of Different Forms of BDD-hFVIII
HA mice (n = 3–5) were injected with LV containing the VEC promoter driving expression of BDD-hFVIII ± miRT-122–142, RH, and co-hFVIII-miRT-122–142.
(A) Two weeks after LV injection, FVIII activity in plasma of injected mice showed an average of 4% for BDD-hFVIII ±miRT-122–142 and RH, and 7% for co-hFVIII-miRT-122–
142. Although hFVIII activity remained stable to 5% in plasma of mice injected with LV.VEC-hFVIII ± miRT-122–142, LV.VEC-RH-, and LV.VEC-co-hFVIII-miRT-122–142-
injected HA mice showed an average of 8% and 11%–12% of hFVIII activity, respectively, and remained stable up to 52 and 36 weeks after injection, and immunization with
FVIII did not affect the FVIII activity in plasma of these mice (p < 0.001 for LV.VEC-cohFVIII-122–142 versus LV.VEC-hFVIII ± 122–142). (B) ELISA showing the absence of anti-
FVIII antibodies in plasma of mice injected with the different LVs. Immunization with FVIII did not result in anti-FVIII antibody production in LV-injected mice. Plasma dilution
was 1:2,000. Ctr+, pooled plasma from LV.PGK-hFVIII-injected mice that developed anti-FVIII antibodies. (A and B) Indicated are means ± SD. (C) Blood loss (mean ± SD)
was evaluated 24 weeks after LV injection bymeasuring the absorbance at 597 nm (A597nm) of blood content in the collection tubes by lysis of red blood cells. (D) Tail bleeding
times (mean ± SD) were assessed by monitoring the blood flow into collection tubes containing saline solution, and times to stop bleeding were recorded. **p < 0.01;
***p < 0.001.
www.moleculartherapy.orgparallel some of our samples, and we found that the chromogenic
assay showed up to 20% higher level than the aPTT assay we nor-
mally perform in the laboratory (Figure S7). However, ELISA for
FVIII-Ag detected higher amount of hFVIII antigen (up to 50%–
60%) compared with both aPTT and chromogenic assays. This
last result was expected because the ELISA evaluates only the pres-
ence of the antigen but not its functionality. We can conclude that
our aPTT measurements underestimated FVIII activity of about
20%, as previously reported by Potgieter et al.51 Taken together,
our data support our hypothesis that endothelial-speciﬁc expres-
sion, even without the miRT-speciﬁc sequences, supports FVIII
expression with FVIII activity without formation of anti-FVIII anti-
bodies in all three different immunoreactive HA mouse strains
studied.DISCUSSION
HA, like HB, is a good candidate for gene therapy because modest
amounts of FVIII or FIX can ameliorate bleeding and improve qual-
ity of life in affected individuals.52 For both diseases, long-term
expression has been successfully achieved in animal models3,13,53–56
and several therapeutic gene transfer strategies have been attempted
in recent years. However, in light of three failed clinical trials for HA,
additional strategies and modiﬁcations of prior approaches are
necessary for long-term therapeutic correction in patients.57 Our
present data demonstrate the potential for using LVs containing
non-hepatocyte liver-speciﬁc promoters in association with post-
transcriptional control sequences (miRTs). As a consequence, trans-
gene expression was selectively restricted to ECs, mainly LSECs for
VEC promoter, or to splenic/hepatic macrophages for the CD11bMolecular Therapy Vol. 25 No 8 August 2017 1823
Figure 7. Effects of Treg Depletion after Gene Therapy with LV.VEC-hFVIII ± 122–142
(A) hFVIII activity in plasma of LV-injected mice reached a level of 4%with LV.VEC-hFVIII ± 122–142 (n = 4 or 5). FVIII activity remained stable up to 10 weeks after LV injection.
hFVIII activity started to decrease 3 weeks after Treg depletion, reached almost undetectable levels, and increased again 16 weeks after Treg depletion, returning to levels
observed before Treg depletion 4 weeks later (p < 0.001, treated mice compared with control HA group). (B) Bethesda units (BU) started to be detected 3 weeks after Treg
depletion and reached the peak 12 weeks after Treg depletion, and then BU decreased again 8 weeks later. (C–E) ELISA showed no anti-FVIII antibodies in plasma of LV-
injected mice up to 14 weeks after LV injection. Three weeks after Treg depletion, the presence of anti-FVIII IgG1 (C), IgG2A (D), and IgG2b (E) was detected in the plasma of
treated mice. Although anti-FVIII IgG2a (D) and IgG2b (E) titers remained high, anti-FVIII IgG1 (C) titers decreased concomitantly with BU 12 weeks after Treg depletion. (A–E)
Indicated are means ± SD. (F) Blood loss (mean ± SD) was evaluated at different times after LV injection by measuring the absorbance at 597 nm (A597nm) of blood content in
the collection tubes by lysis of red blood cells. (G) Tail bleeding times (mean ± SD) were assessed by monitoring the blood flow into collection tubes containing saline solution,
and times to stop bleeding were recorded. n = 3 or 4 per group. **p < 0.01; ***p < 0.001.
Molecular Therapypromoter, resulting in long-term GFP expression in the absence of an
immune response.
The liver has been implicated as the major FVIII-producing organ,
because liver transplantation is able to cure HA in canine models
and humans.58,59 Moreover, hepatocyte-speciﬁc transgene expression
may induce tolerance, reducing the risk for immune reaction against
the transgene; such an approach addresses the current limitations in
reaching therapeutic efﬁcacy with FVIII for HA.52 Previous work
demonstrated the importance of hepatocytes as the main physiologic
source of FVIII. More recently, we and others have demonstrated that1824 Molecular Therapy Vol. 25 No 8 August 2017FVIII is largely secreted by ECs, particularly by LSECs, and to a lesser
extent by hematopoietic cells in both humans and mice.17,19,60–62
In fact, cell therapy approaches demonstrated a role for LSECs
and myeloid cells in FVIII secretion, decreasing bleeding in HA
mice.17,19,27
We thus targeted FVIII expression to endothelial or myeloid cells us-
ing LVs containing endothelial-speciﬁc (LV.VEC)28,40 or myeloid-
speciﬁc (LV.CD11b)29 promoters. Furthermore, the addition of
miRTs in the 30-UTR of the LVs allowed us to reach full cell-
speciﬁc transgene expression. The addition of miRTs-122 or 142-3p
Figure 8. Endothelial-Specific FVIII Expression in Different HA Mouse Strains
(A–D) BALB/c HA mice (n = 4) and B6/129 HA mice (n = 5) were injected with LV.VEC-hFVIII and hFVIII activity (A and C), and eventual presence of anti-FVIII antibodies
(B and D) was evaluated starting from 2 weeks after injection. hFVIII activity in the plasma of LV-injected mice reached 5%–6% up to 28 weeks after injection in BALB/c HA
mice (A), and the same activity was detected in plasma of treated B6/129 HA mice up to 24 weeks after injection. (B and D) ELISA showing no anti-FVIII antibodies in the
plasma of injected BALB/c and B6/129 HA mice up to 28 and 24 weeks, respectively, after injection. Plasma dilutions were 1:200 and 1:2,000. Ctr+, pooled plasma from
LV.PGK-hFVIII-injectedmice that developed anti-FVIII antibodies. (A–D) Indicated aremeans ±SD. (E) Blood loss (mean ±SD) was evaluated 28weeks and 20weeks after LV
injection in BALB/c-HA and B6/129-HA mice, respectively, by measuring the absorbance at 597 nm (A597nm) of blood content in the collection tubes after lysis of red blood
cells. (F) Tail bleeding times (mean ± SD) were assessed by monitoring the blood flow into collection tubes containing saline solution, and times to stop bleeding were
recorded. n = 3–5 per group. **p < 0.01; and ***p < 0.001.
www.moleculartherapy.orgprevented transgene expression in hepatocytes or hematopoietic
cells,48 respectively, in LV.VEC (LV.VEC-122–142). The addition of
miRT-126 prevented FVIII expression in endothelial and pDCs63 inLV.CD11b (LV.CD11b-126). By this strategy, speciﬁc targeting of
ECs, mainly LSECs,17,19 resulted in long-term therapeutic levels of
FVIII expression inHAmice and induced Tregs by a TGF-b-mediatedMolecular Therapy Vol. 25 No 8 August 2017 1825
Molecular Therapymechanism,26 thus inhibiting the immune response. This effect was
observed also in the absence of miRTs, strongly suggesting that the
presence of the endothelial promoter alone is enough to induce
long-term FVIII expression. Additionally, it has been reported that
FVIII expression in hepatocytes could induce a cellular stress, support-
ing our hypothesis that FVIII expression is optimally induced in cells
that are physiologically involved in FVIII expression and secretion.64
In contrast to the limited immune response observed in EC-speciﬁc
FVIII expression, targeting FVIII expression in myeloid cells results
in the formation of anti-FVIII antibodies in 30% of the injected
mice. The addition of miRT-126 to myeloid-speciﬁc FVIII expression
prevents anti-FVIII antibody generation. miR-126 has been reported
to be expressed in pDCs,35 which could be involved, possibly as APC,
in the anti-FVIII adaptive immune response triggered by transgene
expression. Indeed, when we used GFP in LV.CD11b-126 construct,
we observed a strong reduction of GFP expression in pDCs, with no
effect on transgene expression in conventional dendritic cells (cDCs)
and macrophages. Thus, eliminating transgene expression in pDCs
during LV transduction prevents the immune response to the trans-
gene, enabling long-term FVIII secretion and activity. On the other
hand, it was reported that LV delivery activates pDCs to secrete
type I IFN immediately after vector administration, and speciﬁcally
within the liver, contributing to immune-mediated clearance of trans-
duced cells, playing a major role in preventing stable gene transfer.39
In future studies it will be interesting to elucidate the exact mecha-
nism triggering the innate host response in LV-injected animals
with pDC activation and whether IFN production limits LV transduc-
tion of LSEC and myeloid cells as reported for hepatocytes.
Using more active forms of FVIII, such as RH-FVIII and co-
hFVIII,14,45,46,65 we can further increase the therapeutic index of
gene transfer by LV. Similar results were reported by Siner et al.,46
who used this transgene under the control of a hepatocyte-speciﬁc
promoter in AAV-8 to obtain long-term expression without inducing
an immune response. In this context, Nathwani’s group14 reported
phenotypic correction using codon-optimized hFVIII variants
(BDD, N6, and V3) under the control of a hepatocyte-speciﬁc pro-
moter and, by further restricting hFVIII expression in the liver using
AAV-8, obtained a 10-fold increase in transgene expression
compared with the levels obtained using AAV-5.
Finally, we demonstrate stable FVIII activity in the plasma of HA
mice also on BALB/c and B6/129 strains (in addition to C57BL/6)
after injection with EC-speciﬁc LV (LV.VEC-hFVIII). We investi-
gated whether FVIII expression and antibody formation against
the transgene after LV injection would be inﬂuenced by the genetic
background of the HA mice, as previously reported for injection of
recombinant FVIII in HA mice in both C57BL/6 and BALB/c back-
ground.50 The lack of difference in the immune response among
different strains in our data can be explained by the fact that ex-
pressing FVIII in its natural site of production results not only in
long-term FVIII expression but also in the inhibition of a secondary
immune response to FVIII through the direct interaction of effector1826 Molecular Therapy Vol. 25 No 8 August 2017T cells with ECs, mainly LSECs,66 thus endorsing a tolerance
response to FVIII.
In conclusion, our study demonstrates successful long-term expres-
sion of FVIII using LVs speciﬁcally targeting non-hepatocyte cells
in the liver. This approach is complementary to the promising early
clinical trial using AAV to target hepatocyte-speciﬁc FVIII expression
(BMN 270, BioMarin). Because these initial studies select HA patients
without inhibitors, the ﬁnal results may not be applicable to all HA
patients (e.g., those with anti-FVIII inhibitors). As a consequence,
additional strategies to prevent or reverse immune responsiveness
to FVIII may be necessary. We propose that approaches such as those
presented here serve as important pre-clinical models of circumvent-
ing or reversing immune response using non-hepatocyte-speciﬁc
FVIII expression in HA.
MATERIALS AND METHODS
LV Production
We inserted the B-domain-deleted hFVIII (BDD-hFVIII) sequence,
and a de novo synthesized co-hFVIII45 or the RH-hFVIII46 in LV
transfer constructs containing the ubiquitous PGK promoter, the
endothelial-speciﬁc VEC promoter, or the myeloid-speciﬁc CD11b
promoter. LV.PGK-GFP-126, LV.PGK-GFP-142-3p, and LV.PGK-
GFP-122–142-3p constructs were kindly provided by Professor
L. Naldini (HSR-TIGET). We subcloned the miRT sequences from
these constructs into LV.PGK-hFVIII, LV.VEC-GFP, LV.VEC-
hFVIII, LV.CD11b-GFP, and LV.CD11b-hFVIII plasmids.
LVs were produced by transient co-transfection of 293T cells with
third-generation packaging plasmids using the calcium phosphate
method, according to published protocols.67 LV titers were deter-
mined on 293T by qPCR, for hFVIII-containing LV, as previously
described.68
Mice
For in vivo delivery of LVs we used C57BL/6 mice for GFP studies or
HA mice in C57BL/6,27 B6/129, or BALC/c background, obtained by
breeding HA mice in BALB/c for 10 generations. B6/129 HA
(B6;129S-F8tm1Kaz/J, The Jackson Laboratory) mice were kindly pro-
vided by Professor L. Naldini (HSR-TIGET). To induce anti-FVIII
antibodies, mice were injected subcutaneously with 20 mg of ReFacto
in IFA (Sigma-Aldrich), and plasma samples were analyzed from
2 weeks after immunization. Animal studies were performed accord-
ing to an approved protocol by the Animal Care and Use Committee
of Università del Piemonte Orientale.
FVIII Activity Assays
FVIII activity was assessed by aPTT assay, using the Coagulation
Analyzer Coatron M4 (TECOMedical Instruments), and by chromo-
genic assay, using the COATEST SP4 FVIII (Chromogenix, Werfen -
Instrumentation Laboratory). Standard curves were generated using
serial dilutions of pooled human plasma or puriﬁed BDD-hFVIII
(ReFacto) in hemophilic mouse plasma. Results were expressed as
percentage of hFVIII activity.
www.moleculartherapy.orgThe presence of FVIII inhibitors in plasma of treated mice was
assessed using the Nijmegen modiﬁcation of the Bethesda assay, as
previously described.69
ELISA for Anti-FVIII Antibodies and FVIII-Ag
Plasma samples were diluted 1:200 and 1:2,000 and tested in a solid-
phase ELISA, in which ReFacto (0.2 mg/well) or BSA, used as a spec-
iﬁcity control, was adsorbed on PVC microwells and saturated with
0.2% BSA. Serum reactivity was detected with horseradish peroxi-
dase-conjugated goat anti-mouse total IgG (Thermo Fisher Scienti-
ﬁc), IgG1, IgG2a, and IgG2b (Southern Biotec), and the addition
of the chromogen 3,30,5,50-tetramethylbenzidine (TMB; Sigma-
Aldrich). For IgG isotype quantiﬁcation, standard curves of IgG1,
IgG2a, and IgG2b (Southern Biotec) were tested in parallel. Samples
were diluted as described above and pooled plasma from LV.PGK-
hFVIII-injected mice that developed anti-FVIII antibodies or a com-
mercial mouse anti-FVIII monoclonal antibody (Clone GMA-8015,
Green Mountain Antibodies) were used as positive controls. ELISA
for FVIII-Ag detection was performed as reported by McIntosh
et al.14 Absorbance was read at 450 nm on a Victor X (PerkinElmer)
spectrophotometer.
In Vivo Treg Depletion
For Treg depletion, HA mice were injected via the tail vein with 250–
500 mg of anti-CD25 (clone PC61, Bio X Cell) monoclonal antibody
(mAb) kindly provided by Dr. A. Annoni (HSR-TIGET).
To break the tolerance, HA mice were injected with 109 TU of
LV.VEC-hFVIII (n = 5) or LV.VEC-hFVIII-122–142 (n = 4) and,
11 weeks later, injected with anti-CD25 antibodies. Peripheral blood
samples were collected starting 5 days after Treg depletion for Treg
quantiﬁcation by FACS analysis. Plasma was analyzed for hFVIII
activity and for anti-FVIII antibodies.
Immunostaining
Mouse liver and spleen were ﬁxed in 4% paraformaldehyde (PFA) in
PBS for 2 hr at 4C, equilibrated in sucrose, embedded in Killik cryo-
stat embedding medium (Bio-Optica), and stored at –80C; part of
the liver samples were ﬁxed in formalin and enclosed in parafﬁn.
Cryostat sections (5–6 mm) were incubated in blocking buffer, while
5- to 6-mm-thick parafﬁn-embedded mouse liver sections were
treated in boiling 50 mM EDTA (pH 8) for antigen retrieval using
a microwave oven and then blocked in a buffer containing 5% goat
serum, 1% BSA, and 0.1% Triton X-100 in PBS. For FVIII detection,
samples were stained with rabbit anti-FVIII (1:1,000) for 2 hr at room
temperature (RT).19 For GFP detection, samples were stained with
rabbit anti-GFP (1:1,000;Molecular Probes, Thermo Fisher Scientiﬁc)
for 1 hr at RT. In order to characterize GFP- or FVIII-expressing cells,
co-staining was performed with rat anti-mouse F4/80 (1:400; AbD
serotec, Bio-Rad), rat anti-mouse Lyve-1 (1:200; eBioscience, Affyme-
trix), or rat anti-mouse CD31 (1:75; BD PharMingen, BD Biosci-
ences). After washing in PBS containing 0.1% Triton X-100, Alexa
Fluor 488-conjugated goat anti-rabbit IgG and Alexa Fluor 546-con-
jugated goat anti-rat IgG (1:500, Molecular Probes, Thermo FisherScientiﬁc) were added for 1 hr. Nuclei were stained with DAPI
(Sigma-Aldrich). Immunohistochemical reactions were performed
using a standard procedure, as previously reported.19,70 Immuno-
staining was performed with a Dako Cytomation Envision plus sys-
tem (DAKO Cytomation), using diaminobenzidine as a chromogen.
Sections were counterstained with hemalume (Merck).
Liver Cell Isolation
Hepatic cells were isolated by in situ liver perfusion with collagenase
digestion, as previously reported.17,71 Brieﬂy, liver was perfused at
5.5–6 mL/min via the portal vein at 37C for 5 min with buffer con-
taining 1.9 mg/ml EGTA, for 2min with buffer lacking EGTA, and for
12–15 min with buffer containing 0.025% (w/v) collagenase type IV
and 5 mMCaCl2. The perfusion buffer contained 10 mmol/L HEPES,
3 mmol/L KCl, 130 mmol/L NaCl, 1 mmol/L NaH2PO4$H2O, and
10 mmol/l D-glucose (pH 7.4). The liver was dissociated, and cells
were ﬁltered through Dacron fabric with 80 mmpores and centrifuged
at 50  g for 5 min to isolate hepatocytes. Non-parenchymal cells
(NPCs) in the supernatant were pelleted at 350  g for 10 min, and
after red blood cell lysis for 6 min on ice, LSECs or KCs were immu-
nomagnetically selected using anti-CD146 or anti-CD11b + anti-F4/
80 (Miltenyi Biotec), respectively. Chemicals and collagenase were
from Sigma-Aldrich.
Genomic DNA Isolation and qPCR
Genomic DNA (gDNA) was isolated from cells, liver, or spleen sam-
ples using the ReliaPrep gDNA Tissue Miniprep System (Promega).
gDNA (50 ng) was used for the qPCR using the GoTaq qPCR Master
Mix (Promega). The PCR protocol was as follows: initial denaturation
at 95C for 10 min followed by 35 cycles of denaturation at 95C for
30 s, annealing, and extension at 60C for 45 s. Primers used were
GAPDH (sense: atcactgccacccagaagact; antisense: atcgaaggtggaagagt
ggga) and Wpre-dNEF (sense: tggattctgcgcgggacgtc; antisense: ggctaa
gatctacagctgccttg). Copy number was assessed for each sample by
comparison with GAPDH and LV standard curves.
Flow Cytometric Analysis
For hepatic and splenic pDCanalysis, livers and spleenswere harvested
and processed as previously described.35 Samples were stained with
PE-conjugated anti-mouse CD11c (Miltenyi Biotec) or PE-conjugated
anti-mouse B220 (eBioscience, Affymetrix) andAPC-conjugated anti-
mouse PDCA-1 (Miltenyi Biotec). For Treg analysis, peripheral blood
was collected and analyzed using FACSCalibur for CD4, CD25, and
Foxp3 expression starting 5 days after anti-CD25 injection using the
Mouse Regulatory T Cell Staining Kit #2 (eBioscience, Affymetrix).
For Treg FACS analysis, we used another clone of anti-mouse CD25,
clone 7D4 (Miltenyi Biotec), to avoid FACS staining problems caused
by using the same clone as was used for Treg depletion. For each sam-
ple, 1–2  105 events were acquired by FACSCalibur. Data were
analyzed using FlowJo software (Tree Star).
Tail Clip Challenge
Tail clip assay was performed as previously described.72 Brieﬂy, mice
were anesthetized, and tail tips (2.5–3 mm in diameter) were cut andMolecular Therapy Vol. 25 No 8 August 2017 1827
Molecular Therapyimmersed in saline at 37C. Bleeding was carried on for a maximum
of 10 min; tails were then removed from saline solution and cauter-
ized. Times to stop bleeding were recorded, and the amount of blood
loss was evaluated by centrifuging and resuspending samples in red
blood lysis buffer. Absorbance was read at 597 nm on a Victor X
(PerkinElmer).
Statistical Analysis
Data are shown as mean ± SD. Signiﬁcance was analyzed using t tests
and one-way or two-way ANOVA with Bonferroni post hoc tests in
GraphPad Prism version 5 (GraphPad Software); p values < 0.05
were considered to indicate statistical signiﬁcance.
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